CLINICAL_TRIALS
trial_result
· 2021-12-23
Clinical Trial Update: TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) [Phase 2]
Summary
Phase 2 trial of TLC399 (ProDex) in macular edema due to retinal vein occlusion completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Taiwan Liposome Company | Conditions: Retinal Vein Occlusion, Macula Edema | Phase 2 | Status: COMPLETED | Results posted: 2021-12-23